|This article is of interest to the following WikiProjects:|
Histone Modifications in Telomeres
I removed this section from the main wikipedia page because it is likely only of interest to specialists (maybe just the author shilling their own work?) and the article is already too sprawling and hard to read.
The telomeres of human cells have been found to have a unique histone modification pattern, with the most enriched modifications being H2BK5me1 and H3K3me3 and the least enriched modifications being H3K36me3 and H3K9me3 
- Rosenfeld, Jeffrey A; Wang, Zhibin; Schones, Dustin; Zhao, Keji; DeSalle, Rob; Zhang, Michael Q (31 March 2009). "Determination of enriched histone modifications in non-genic portions of the human genome.". BMC Genomics. 10 (143): 143. doi:10.1186/1471-2164-10-143. PMC . PMID 19335899. Unknown parameter
@Dan Eisenberg: reverted my edits, asking me not to post abstracts of my articles. I presume he thinks I wrote the source in question. Not me. I do not edit war, but I think the revert is unwarranted and would appreciate the thoughts of other editors. The paragraph in question is:
- A 2016 phase 1–2 prospective study orally administered 800 mg per day to 27 patients with telomere diseases. The primary efficacy endpoint was a 20% reduction in the annual rate of telomere attrition measured. Toxic effects formed the primary safety endpoint. The study was halted early, after telomere attrition was reduced in all 12 patients who could be evaluated. 12 of 27 patients achieved the primary efficacy end point, 11 of whom increased telomere length at 24 months. Hematologic responses (secondary efficacy endpoint) occurred in 10 of 12 patients who could be evaluated at 24 months. Elevated liver-enzyme levels and muscle cramps (known adverse effects) of grade 2 or less occurred in 41% and 33% of the patients, respectively.
Telomeres and cancer section
There is an awful lot of information on Telomerase in the cancer and Telomerase section. I believe this should be moved to the Telomerase page, however I do not have much expertise on the subject and so open up a request for someone else to edit this?
Also, I plan to work on the ALT section. I don't know about moving this out into a separate article for the time being; there is not much information and I feel it fits well into the Telomere article after the re-jig.--Rachemon (talk) 18:03, 10 August 2016 (UTC)
- Townsley, Danielle M.; Dumitriu, Bogdan; Liu, Delong; Biancotto, Angélique; Weinstein, Barbara; Chen, Christina; Hardy, Nathan; Mihalek, Andrew D.; Lingala, Shilpa (2016-05-18). "Danazol Treatment for Telomere Diseases". New England Journal of Medicine. 374 (20): 1922–1931. doi:10.1056/nejmoa1515319.